157 related articles for article (PubMed ID: 36919403)
1. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
[TBL] [Abstract][Full Text] [Related]
2. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
3. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
[TBL] [Abstract][Full Text] [Related]
4. A randomized Bayesian optimal phase II design with binary endpoint.
Ding Y
J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
[TBL] [Abstract][Full Text] [Related]
5. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
6. Interpreting a Bayesian phase II futility clinical trial.
Beall J; Cassarly C; Martin R
Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
[TBL] [Abstract][Full Text] [Related]
7. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
Sambucini V
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
[TBL] [Abstract][Full Text] [Related]
8. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
Arjas E; Gasbarra D
BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
[TBL] [Abstract][Full Text] [Related]
9. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
[TBL] [Abstract][Full Text] [Related]
10. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
11. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
Ryan EG; Brock K; Gates S; Slade D
BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
[TBL] [Abstract][Full Text] [Related]
12. Bayesian single-arm phase II trial designs with time-to-event endpoints.
Wu J; Pan H; Hsu CW
Pharm Stat; 2021 Nov; 20(6):1235-1248. PubMed ID: 34085764
[TBL] [Abstract][Full Text] [Related]
13. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
[TBL] [Abstract][Full Text] [Related]
14. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
Ryan EG; Lamb SE; Williamson E; Gates S
Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
Stallard N; Todd S; Ryan EG; Gates S
BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
[TBL] [Abstract][Full Text] [Related]
16. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
Kaizer A; Zabor E; Nie L; Hobbs B
PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
[TBL] [Abstract][Full Text] [Related]
17. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development.
Broglio K; Cooner F; Wu Y; Xiao M; Xue XQ; Lowen M; Ikhapoh I; He P
Ther Innov Regul Sci; 2024 Jun; ():. PubMed ID: 38861131
[TBL] [Abstract][Full Text] [Related]
19. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
Bretz F; Schmidli H; König F; Racine A; Maurer W
Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
[TBL] [Abstract][Full Text] [Related]
20. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
Schmidli H; Bretz F; Racine A; Maurer W
Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]